抑肝散用于接受高侵袭性手术癌症患者围手术期精神症状:J-SUPPORT 1605(ProD研究)随机对照试验方案
本研究为随机双盲安慰剂对照试验,旨在明确抑肝散对癌症患者术前焦虑的治疗效果及对术后谵妄的预防效果,并确认其安全性。计划每组入组110例、共220例,主要终点为术前焦虑变化和术后谵妄发生率。
要点
- 抑肝散可能改善癌症患者术前焦虑并预防术后谵妄。
- 研究采用随机双盲安慰剂对照设计,计划入组220例。
- 主要终点为术前焦虑变化和术后谵妄发生率。
核心结论
- 本研究旨在明确抑肝散对癌症患者围手术期精神症状的治疗与预防效果及安全性。
研究设计与样本
- 随机双盲安慰剂对照试验,纳入计划行肿瘤切除术的癌症患者,目标入组每组110例、共220例。
- 研究药物在手术前口服给药并持续4天或更长时间。
关键数值与推荐
- 主要终点为术前焦虑变化和术后谵妄发生率。
- 次要终点包括术后谵妄严重程度评分、术后谵妄持续时间、术前苯二氮䓬类药物使用量、术后抗精神病药物使用量及术后住院天数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preoperative anxiety and postoperative delirium affect both short- and long-term prognoses in patients with cancer; therefore, these conditions require early prevention and treatment. However, no standard preventive or therapeutic methods have been established for them. Yokukansan, a Japanese herbal medicine for the treatment of insomnia and anxiety, causes relatively few adverse drug reactions and effectively improves the behavioral and psychological symptoms of dementia. Thus, it is expected to be useful for treating and/or preventing perioperative psychiatric symptoms in patients with cancer. The objective of this study is to clarify the therapeutic effect of Yokukansan for preoperative anxiety and its preventive effect on postoperative delirium in cancer patients, as well as to confirm its safety profile. METHODS: This study is a randomized, double-blind, placebo-controlled study in cancer patients scheduled to undergo tumor resection. Patients who provide consent are randomly allocated to receive oral administration of Yokukansan or placebo, and study drug administration is continued for 4 days or longer prior to surgery. We defined two primary endpoints, change in preoperative anxiety and incidence of postoperative delirium. Secondary endpoints are severity score of postoperative delirium, duration of postoperative delirium, amount of benzodiazepines used prior to surgery, amount of antipsychotic agents used after surgery, and number of postoperative hospitalization days. We plan to complete the analysis on March 31, 2021. The target number of registered patients is 110 per group, or 220 in total. DISCUSSION: This study is the first randomized, double-blind, placebo-controlled study intended to clarify the effects of a Japanese herbal medicine, Yokukansan, in the prevention and treatment of perioperative psychiatric symptoms in patients with cancer. The trial was initiated on August 14, 2017, with 195 subjects randomized by October 5, 2018. TRIAL REGISTRATION: UMIN Clinical Trials Registry (UMIN-CTR), UMIN000027561 . Registered on 31 May 2017.
引用
- Wada S, Sadahiro R, Matsuoka YJ, et al. Yokukansan for perioperative psychiatric symptoms in cancer patients undergoing high invasive surgery. J-SUPPORT 1605 (ProD Study): study protocol for a randomized controlled trial. Trials. 2019. PMID: 30736826. doi:10.1186/s13063-019-3202-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。